Picture [LSUS] – The Business Web Portal 650x65px
Organisation › Details

Covagen AG

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer. Fynomers are small binding proteins that can be engineered to bind an antigen of interest. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Covagen is a privately held Swiss Biotech company with an internal lead bispecific anti-TNF/IL-17A FynomAb moving towards first-in-human Phase 1 studies in early 2014. In 2012, Covagen entered into a strategic alliance, which was recently expanded, with Mitsubishi Tanabe Pharma Corporation for the development of bispecific FynomAbs. *


Period Start 2007-01-08 splitoff
  Group Johnson & Johnson (JnJ) (Group)
  Predecessor ETH Zürich (ETHZ)
Products Industry FynomAb technology
  Industry 2 COVA322 (Covagen)
Persons Person Bertschinger, Julian (Covagen 200701– CEO + co-founder)
  Person 2 Grabulovski, Dragan (Covagen 200701– CSO + co-founder)
Region Region Schlieren ZH
  Country Switzerland
  Street 25 Wagistr.
  City 8952 Schlieren ZH
  Tel +41-44-732-4660
    Address record changed: 2018-07-24
Basic data Employees n. a.
    * Document for �About Section�: Covagen AG. (12/9/13). "Press Release: Covagen Secures CHF 42 Million in Series B Financing". Zürich-Schlieren.
Record changed: 2019-01-16


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Johnson & Johnson (JnJ) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top